Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

17.0K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
17.0K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

4.0K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
4.0K
Lampbrush Chromosomes01:51

Lampbrush Chromosomes

8.9K
In 1882, Flemming observed lampbrush chromosomes (LBC) in salamander eggs. Later in 1892, Rückert observed LBCs in shark egg cells and coined the term "lampbrush chromosomes" because they looked like brushes used to clean kerosene lamps.
LBCs are made up of two pairs of conjugating homologous chromatids. Each chromatid consists of alternatively positioned regions of condensed-inactive chromatin and loosely placed-active side loops, which can be contracted and extended. The loops...
8.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

Intensive care medicine·2026
Same author

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.

Oncology and therapy·2026
Same author

Risk factors for severe post-COVID condition in children, adolescents, and young adults.

European journal of pediatrics·2026
Same author

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Blood·2026
Same author

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

The New England journal of medicine·2025
Same author

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Blood·2025

Related Experiment Video

Updated: Apr 15, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K

[Chronic lymphatic leukemia].

Manuela Bergmann1, Clemens-Martin Wendtner1

  • 1Klinikum Schwabing, Klinik für Hämatologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, München.

Deutsche Medizinische Wochenschrift (1946)
|April 1, 2015
PubMed
Summary

Chronic lymphocytic leukemia (CLL) is a common leukemia in the Western world. New chemo-free treatments targeting B-cell receptor signaling and Bcl-2 proteins offer promising alternatives to traditional chemotherapy.

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.3K

Related Experiment Videos

Last Updated: Apr 15, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.3K

Area of Science:

  • Hematology
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in Western countries, typically diagnosed in older adults.
  • Diagnosis relies on identifying specific B-lymphocyte counts and surface markers (CD5, CD19, CD20, CD23) via flow cytometry.
  • Assessing 17p deletion and TP53 mutation status is crucial before initiating treatment.

Purpose of the Study:

  • To review current treatment standards for Chronic lymphocytic leukemia (CLL).
  • To explore emerging chemo-free treatment options for CLL patients.
  • To discuss the impact of novel agents on future CLL management strategies.

Main Methods:

  • Review of current clinical guidelines and therapeutic standards for CLL.
  • Analysis of recent clinical trial data for novel CLL therapies.
  • Discussion of targeted agents including monoclonal antibodies, BTK inhibitors, PI3K inhibitors, and BH3 mimetics.

Main Results:

  • Immunochemotherapy (FCR) remains a standard for fit patients, with BR and ofatumumab as alternatives.
  • Physically compromised patients may receive chlorambucil with anti-CD20 antibodies.
  • Novel agents like ibrutinib, idelalisib, and ABT-199 show promise for chemo-free strategies, with obinutuzumab demonstrating efficacy in elderly patients.

Conclusions:

  • Chemo-free or chemo-reduced treatment concepts are becoming increasingly viable for CLL management.
  • Targeted therapies offer new hope and improved outcomes for CLL patients.
  • The evolving landscape of CLL treatment necessitates personalized approaches based on patient condition and disease characteristics.